Secretome Therapeutics

Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01. "This partnership with Secretome Therapeutics represents an exciting opportunity for Cellipont to support the advancement of cutting-edge cell therapies," said?Darren Head, CEO of Cellipont Bioservices. "We are very excited to collaborate with a company so dedicated to developing innovative solutions that address significant unmet medical needs and improve patient outcomes." "A key objective for Secretome in 2025 is to produce STM-01 drug product that is suitable for late-stage clinical testing and potential commercial use," said?Vinny Jindal, President and CEO of Secretome Therapeutics. "Cellipont's world-class facility and deep expertise in cGMP manufacturing for cell and gene therapies make them an ideal manufacturing partner and align perfectly with our mission to deliver transformative therapies for cardiovascular diseases and beyond."

The capital raised in this round will support operations through mid-2026 and fund key initiatives, including: Clinical Trials:?Launching two Phase 1 trials of STM-01 in HFpEF (heart failure with preserved ejection fraction) and DCM (dilated cardiomyopathy), with proof-of-concept data expected in Q3 2025. Manufacturing Scale-Up:?Transitioning STM-01 manufacturing to 3-dimensional bioreactor technology. Pipeline Development:?Advancing STM-21 and other preclinical programs to address inflammatory conditions. Regulatory Engagement:?Defining the regulatory pathway for STM-01 in orphan indications. Intellectual Property:?Submitting patents on next-generation cell and secretome products following the issuance of composition patents for STM-01 and STM-21.

“With these patents in place, we can confidently move our development candidates forward as we prepare to launch two Phase 1 studies for STM-01 by the end of this year,” said Vinny Jindal, President and CEO of Secretome Therapeutics. “These patents not only protect the molecular integrity of STM-01 and STM-21 but also underscore our potential to develop multiple products derived from nCPC for the treatment of a wide array of diseases driven by chronic inflammation.”

“This investment comes at a pivotal moment as we advance our lead asset, STM-01, into two Phase I clinical studies next quarter,” Vinny Jindal, president and CEO at Secretome Therapeutics, said in a statement. “The support from HEST Investments provides us with capital and aligns us with a partner who shares our vision for making groundbreaking advances in healthcare.”